Compare Natera Inc. Common Stock (NTRA) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Prologis Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Prologis Inc trades at $131.89 (market cap $126.92B). The key difference: Prologis Inc is far larger — about 2.2× Natera Inc. Common Stock's market cap, and Prologis Inc pays a 3.2% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Prologis Inc for 102 Days on average.
| NTRA | PLD | |
|---|---|---|
Market Cap | $57.03B | $126.92B |
Volume | 1,131,157 | 4,456,134 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $149.96 |
52-Week Low | $179.42 | $121.17 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $56.18B | $161.66B |
Dividend Yield | — | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Prologis (PLD) trades at $130.53, down 1.46% on the day, with strong fundamentals including 45.79% net income margin and consistent earnings beats. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages, trading near support at $130. Recent news highlights leasing growth and data center expansion opportunities, while institutional buying continues.
Outlook remains positive with 61.9% analyst buy ratings and $155.15 consensus target offering 19% upside. Key risks include elevated valuation multiples (P/E 29.74) and rising debt-to-asset ratio (37.2% in 2025). The company's logistics real estate portfolio benefits from e-commerce and data center demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
